BioSpace News Archive

Senda Biosciences, Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.

The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

Revive Therapeutics Ltd. announces it will submit an updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include additional supporting information and the data from the independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto.

IsoPlexis Corporation today announced its preliminary unaudited revenue for the full year ended December 31, 2022.

Comera Life Sciences Holdings, Inc. today announced it will present at the 22 nd Annual PepTalk Conference, in San Diego on Wednesday, Jan. 18, 2023 at 5:15 p.m. PT.

Shuttle Pharmaceuticals Holdings, Inc. announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor.

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

CVRx, Inc. announced that it plans to release fourth quarter and full year 2022 financial and operating results after market close on Thursday, January 26, 2023.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET.

StageZero Life Sciences, Ltd. announces that it has applied to the Toronto Stock Exchange to extend the expiry date of 6,492,420 outstanding common share purchase warrants expiring the 16th and 31st of January, 2023, to January 31, 2024.